Clinical Study Results, Full-Year Guidance, Upcoming Earnings Schedules, and Trial Completions - Research Report on Covidien, Mallinckrodt, The Medicines Company, Catalyst, and Akorn PR Newswire NEW YORK, October 23, 2013 NEW YORK, October 23, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Covidien plc, Mallinckrodt plc (NYSE: MNK), The Medicines Company (NASDAQ: MDCO), Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), and Akorn, Inc. (NASDAQ: AKRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Covidien plc Research Report On October 14, 2013, Covidien plc (Covidien) announced that it has released positive final results from its DURABILITY II study, and promising preliminary data from its DEFINITIVE AR trial, both demonstrating the safety and effectiveness of technologies used in the treatment of peripheral arterial disease (PAD). Covidien stated that it presented the said results at the Vascular Interventional Advances (VIVA) 2013 conference, held in Las Vegas, Nevada. The Company informed that the DURABILITY II three-year results supported the use of a single long EverFlex self-expanding stent, while the DEFINITIVE preliminary data showed early success with the combined use of directional atherectomy and a drug-coated balloon (DAART) in treating lower limb blockages in PAD patients. The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a14c_COV] -- Mallinckrodt plc Research Report On October 16, 2013, Mallinckrodt plc (Mallinckrodt) announced financial guidance for full-year FY 2014 (period ending September 26, 2014). The Company stated that for full-year FY 2014, it expects annual net sales to be in the range of $2.15 billion to $2.25 billion on an operational basis, which excludes impact of foreign exchange fluctuations. The Company informed that it expects net sales of around $885 million to $930 million for the Global Medical Imaging segment and net sales of between $1.2 billion to $1.3 billion for the Specialty Pharmaceuticals segment. The Company added that adjusted diluted EPS is expected to be in the range of $2.45 to $2.65 for full-year FY 2014. Mark Trudeau, President and CEO of Mallinckrodt said, "Fiscal 2014, our first full year as an independent public company, will be an important one as we advance new branded products through the regulatory process and make strategically important investments in our go-to-market capabilities. Beyond building our pipeline and marketing capabilities in specialty pharmaceuticals, we remain committed to becoming more efficient, as demonstrated by the three-year restructuring program we announced in August 2013." The Full Research Report on Mallinckrodt plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/24f6_MNK] -- The Medicines Company Research Report On October 9, 2013, The Medicines Company announced the completion of two pharmacodynamics trials that evaluated the transition of its investigational acute intravenous antiplatelet agent, cangrelor, to chronic oral therapy with ticagrelor or prasugrel in patients with coronary artery disease (CAD). According to the Company, the ticagrelor and prasugrel transition studies were each conducted in 12 CAD patients to test the consistency of inhibition of platelet aggregation when oral ticagrelor or prasugrel were administered during or immediately after cangrelor infusion. The Company informed that the objective of these trials was to demonstrate that patients treated with IV cangrelor can be directly transitioned to the oral drug without a significant decrease in the extent of inhibition of platelet aggregation. Simona Skerjanec PharmD, MBA, Senior Vice President and Innovation Leader for Antiplatelet Therapies at the Medicines Company said, "Completion of both these studies evaluating the transition to newer oral agents enables us to add to the wealth of data that informs cangrelor dosing and administration which is under regulatory review." The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5a84_MDCO] -- Catalyst Pharmaceutical Partners, Inc. Research Report On October 15, 2013, Catalyst Pharmaceutical Partners, Inc. (Catalyst) announced that the independent Data Monitoring Committee (DMC) overseeing Catalyst's ongoing pivotal Phase III clinical trial in the US and Europe that evaluated Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) has recommended continuation of the trial by Catalyst, as planned, based on the committee's review of safety and clinical data from the trial. The Company informed that it has initiated 12 additional sites, in addition to seven active sites at the time of acquisition, and also expects to initiate shortly an additional six sites in the US, Europe, Canada, and South America. Catalyst stated that it expects to complete the enrollment in the trial by the end of Q4 2013, and to announce top line data from the trial during Q2 2014. The Full Research Report on Catalyst Pharmaceutical Partners, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a791_CPRX] -- Akorn, Inc. Research Report On October 14, 2013, Akorn, Inc. (Akorn) announced that it will release Q3 2013 earnings before the market opens on Tuesday, November 5, 2013. The Company informed that it will also host a conference call to discuss its quarterly results on the same day at 10:00 a.m. ET, which will be followed by a Q&A session. Akorn stated that a live broadcast of the call will be available at its website under the Investor Relations section and a replay of the same will also be available for 30 days after the completion of the call. The Full Research Report on Akorn, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/900c_AKRX] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Study Results, Full-Year Guidance, Upcoming Earnings Schedules, and Trial Completions - Research Report on Covidien,
Press spacebar to pause and continue. Press esc to stop.